文献速递妇科

放疗期间肿瘤大小、体积和标志物表达可预测宫颈癌患者生存:KROG 16-01多机构回顾性分析

Tumour size, volume, and marker expression during radiation therapy can predict survival of cervical cancer patients: a multi-institutional retrospective analysis of KROG 16-01.
PubMed 文献 · Gynecol Oncol · 2017-10-27

本研究为多机构回顾性分析,纳入231例FIGO Ib2-IVa期宫颈癌患者,在放疗前和放疗中行盆腔MRI及鳞状细胞癌抗原(SCC-ag)检测。多因素分析显示,分期、肿瘤体积缩小率(TVRR)和SCC-ag下降率(SCCRR)与总生存(OS)独立相关;放疗前肿瘤大小(TS)、放疗中肿瘤体积(TV)和SCCRR与无进展生存(PFS)相关。预后风险评分最高3分的患者OS和PFS较差。

要点

  • TVRR、SCCRR、放疗前TS和放疗中TV是宫颈癌放疗患者的独立强预后参数。
  • 基于评分系统的预后因素分析可帮助制定放疗期间的优化治疗方案。
  • 预后风险评分最高3分者OS和PFS较低评分者差。

核心结论

  • TVRR、SCCRR、放疗前TS和放疗中TV是接受放疗的宫颈癌患者的独立强预后参数。
  • 基于评分系统的预后因素分析可帮助为放疗期间的宫颈癌患者制定优化治疗方案。

研究设计与样本

  • 多机构回顾性分析,纳入231例组织学确诊的FIGO Ib2-IVa期宫颈癌患者。
  • 在放疗前和放疗中(近距离治疗前)行盆腔MRI和SCC-ag分析两次。

主要发现

  • 中位随访时间27.8个月(范围2-116个月)。
  • 多因素分析显示,分期(OR 2.936,95%CI 1.119-7.707;P=0.029)、TVRR(OR 3.435,95%CI 1.062-11.106;P=0.039)和SCCRR(OR 5.104,95%CI 1.769-14.727;P=0.003)与OS独立相关。
  • 放疗前TS(OR 2.148,95%CI 1.221-3.810;P=0.009)、放疗中TV(OR 3.106,95%CI 1.685-5.724;P<0.0001)和SCCRR(OR 1.954,95%CI 1.133-3.369;P=0.016)与PFS相关。
  • 预后风险评分最高3分的患者OS和PFS较低评分者差。

临床怎么用

  • 作者认为,基于评分系统的预后因素分析可帮助为放疗期间的宫颈癌患者制定优化治疗方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this multi-institutional study was to determine the prognostic impact of tumour parameters, such as tumour size (TS), tumour volume (TV), and marker expression, on survival during radiation therapy (RT) for cervical cancer patients. METHODS: A total of 231 patients with histologically confirmed cervical cancer, classified as Federation of Gynecology and Obstetrics (FIGO) Ib2-IVa, were enrolled in this study. Pre- and mid-RT pelvic magnetic resonance imaging (MRI) and squamous cell carcinoma antigen (SCC-ag) analysis were performed twice, during RT and just before brachytherapy. RESULTS: The median follow-up time was 27.8months (range, 2-116months). Multivariate analysis revealed that stage (odds ratio [OR], 2.936 and 95% confidence interval [CI], 1.119-7.707; P=0.029), tumour volume reduction rate (TVRR) (OR, 3.435 and 95% CI, 1.062-11.106; P=0.039), and SCC-ag reduction rate (SCCRR) (OR, 5.104 and 95% CI, 1.769-14.727; P=0.003) were independently associated with overall survival (OS), while pre-RT TS (OR, 2.148 and 95% CI, 1.221-3.810; P=0.009), mid-RT TV (OR, 3.106 and 95% CI, 1.685-5.724; P<0.0001) and SCCRR (OR, 1.954 and 95% CI, 1.133-3.369; P=0.016) were associated with progression-free survival (PFS). Based on the prognostic factor analysis, patients with the highest prognostic risk score of 3 showed poorer overall survival and progression free survival than patients with lower prognostic risk scores. CONCLUSION: We identified that tumour parameters such as TVRR, SCCRR, pre-RT TS, and mid-RT TV areindependent and strong prognostic parameters for patients with cervical cancer receiving RT. This scoring system-based prognostic factor analysis could be used to help develop optimized treatment plans for cervical cancer patients during RT.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Lee JH, Lee SW, Kim JR, et al. Tumour size, volume, and marker expression during radiation therapy can predict survival of cervical cancer patients: a multi-institutional retrospective analysis of KROG 16-01. Gynecol Oncol. 2017. PMID: 29110878. doi:10.1016/j.ygyno.2017.09.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。